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Alkylating agents that damage DNA and are used extensively of Pathology and Biochemistry, University of Washington, Seattle, WA 98195-7705, USA in cancer chemotherapy are also mutagenic and carcinogenic. They alkylate DNA at multiple sites on nucleotide bases, 2 Present address: Affymetrix, 3380 Central Expressway, Santa Clara, sugars and phosphates; yet there is substantial agreement that CA 95051, USA the major mutagenic and lethal lesions involve the O 6 3 To whom correspondence should be addressed position of guanine. Repair of O 6 -alkylguanine (O 6 -alkG) is Email: bb1pucuc@uco.es carried out predominantly by O 6 -alkylguanine-DNA alkyl-O 6 -alkylguanine-DNA alkyltransferase (AGT) is a suicide transferase (AGT). This enzyme attenuates the mutagenic protein that corrects DNA damage by alkylating agents and lethal effects of methylating and ethylating agents in and may also serve to activate environmental carcinogens.
virtually all organisms studied (1, 2) , and the levels of this We expressed human wild-type and two active mutant enzyme in tumors frequently parallel the response of the AGTs in bacteria that lack endogenous AGT and are also tumors to chemotherapeutic bifunctional haloethylnitrosoureas defective in nucleotide excision repair, to examine the [e.g. 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)]. ability of the AGTs to protect Escherichia coli from DNA Treatment of patients with alkylating agents is usually limited damage by different types of alkylating agents and, by myelosuppression due to the cytotoxic effects of these oppositely, to sensitize cells to the genotoxic effects of agents on bone marrow. As a result it has been proposed that dibromoalkanes (DBAs). Control bacteria carrying the the enhanced expression of AGT or mutant AGTs could protect cloning vector alone were extremely sensitive to mutagenbone marrow cells and permit dose escalation of therapeutic esis by low, noncytotoxic doses of N-methyl-NЈ-nitro-Nalkylating agents.
nitrosoguanidine (MNNG). Expression of human wild-type
Previous studies from one of our laboratories (6,7) suggested AGT prevented most of this enlarged susceptibility to a new role for AGT in activating dibromoalkanes (DBAs) to MNNG mutagenesis. Oppositely, cell killing required much enhance their reactivity with DNA, thus increasing toxicity, higher MNNG concentrations and prevention by wild-type mutagenesis and carcinogenesis. 1,2-Dibromoethane (DBE), AGT was much less effective. Mutants V139F and V139F/ used extensively in industry (3) , is mutagenic in microorgan-P140R/L142M protected bacteria against MNNG-induced isms, yeast and other fungi, plants, insects, mammals and cytotoxicity more effectively than the wild-type AGT, but human cells (4) . DBE is also carcinogenic in experimental protection against the less stringent mutagenesis assay was animals, and probably carcinogenic to humans (5). When variable. Subtle differences between wild-type AGT and human or bacterial AGT was expressed in Escherichia coli, a the two mutant variants were further revealed by assaying significant increase in mutagenesis and cytotoxicity was protection against mutagenesis by more complex alkylating observed following exposure to both DBE and dibromomethane agents, such as N-ethyl-N-nitrosourea and 1-(2-chloro-(DBM) (6, 7) . This unexpected finding was the first evidence ethyl)-3-cyclohexyl-1-nitrosourea. Unlike wild-type and that a DNA repair protein can enhance, rather than prevent, V139F, the triple mutant variant, V139F/P140R/L142M the genotoxicity of environmental chemical carcinogens. was unaffected by the AGT inhibitor, O 6 -benzylguanine.
The availability of mutant AGTs has facilitated studies on Wild-type AGT and V139F potentiated the genotoxic effects the function of this enzyme in the repair of DNA damage of DBAs; however, the triple mutant virtually failed to by alkylating agents and now in the activation of DBAs. sensitize the bacteria to these agents. These experiments Random mutagenesis was followed by positive genetic selecprovide evidence that in addition to the active site cysteine tion to create large libraries of human AGTs. The mutant at position 145, the proline at position 140 might be enzymes were then selected on the basis of complementing important in defining the capacity by which AGTs modulate AGT-deficient E.coli (8 marrow by gene therapy in patients who receive high doses ences between slopes were done by regression ANOVA analysis. P-values for some of the comparisons are indicated in the text. For survival determinations in the presence and absence of BG,~10 5 bacteria were exposed to each dose of mutagen, as described above. Following mutagen treatment, aliquots of 0.1 ml (~10 4 bacteria) were combined in 2 ml of molten top agar and plated on LB nutrient agar (VB minimal medium plates for ENU and CCNU) with carbenicillin (50 µg/ml). Bacterial colonies were counted automatically (Analytical Measuring System Ltd., UK, model 40-10). All data represent averages from at least two duplicate plates. Each assay was repeated on at least two separate occasions using a wide range of mutagen concentrations.
Results
Protection from alkylating agents by AGT and variants V139F and V139F/P140R/L142M are mutant AGTs that were previously selected from random libraries in bacteria lacking AGT for their ability to confer resistance to the methylating agent, MNNG. The triple mutant, V139F/P140R/L142M was identified by screening the library for resistance to MNNG ϩ BG (8) . Larger alkyl groups that are substrates for AGT are also subject to removal by nucleotide excision repair. In these studies, we utilized bacteria that lack both AGT and nucleotide of alkylating agents, as well as in patients who are to receive excision repair pathways so that the role of AGT in protecting BG to overcome the recalcitrant resistance of many tumors to against compounds ( Figure 1 ) that generate larger adducts alkylation-based chemotherapeutic regimens (9) . Here we could be examined. compare the ability of these two mutants and wild-type AGT Survival and mutagenesis were quantitated following treatin protecting E.coli against the lethal and mutagenic effects of ment of repair-defective bacteria expressing either wild-type the ethylating agent N-ethyl-N-nitrosourea (ENU), and the AGT, V139F or V139F/P140R/L142M with varying concentrachloroethylating chemotherapeutic agent CCNU. To explore tions of MNNG Ϯ 100 µM BG (Figure 2 ). Cell death occurred the putative mechanism by which AGT plays a role in the at higher concentrations of MNNG than that required for sensitization towards DBA genotoxicity, the cytotoxicity and mutagenesis, which is in agreement with previous results (8) . mutagenesis induced by DBE and DBM were also quantified.
As expected, MNNG was the most toxic to bacteria expressing the vector alone, while the mutants, V139F and V139F/P140R/ Materials and methods L142M offered the cells enhanced protection over wild-type directed or random sequence mutagenesis, and their putative utilities for gene therapy have been initially inferred on the basis of the mutants being able to prevent an AGT-defective size of the alkyl group increases. V139F offered better protecstrain of E.coli from killing by high (and in some cases tion than V139F/P140R/L142M against ENU and CCNU multiple) doses of MNNG (~70-270 µM) (8, 13, 14) . The mutagenesis (P Ͻ 0.01), but in contrast to the MNNG results, induction of L-arabinose resistance provides a sensitive forward this protection was similar to that exhibited by wild-type AGT mutation assay for detection and quantification of the mutagenic (P ജ 0.21). This order of effectiveness was maintained in potency of chemical carcinogens (15,16). We utilized this protection against killing by either ENU or CCNU, where sensitive mutagenesis assay to evaluate the ability of human wild-type AGT µ V139F Ͼ V139F/P140R/L142M (Figure wild-type AGT and two mutant variants of AGT to protect 4). As was the case with MNNG, the protective ability of E.coli from DNA damage by different types of alkylating V139F/P140R/L142M against ENU and CCNU mutagenesis agents and, oppositely, to sensitize cells to the genotoxic was unaffected by BG (P ജ 0.41), while both V139F and effects of DBAs. Bacteria that lacked endogenous AGT activity wild-type AGT were highly sensitive to this inhibitor (Figure were also defective in nucleotide excision repair (ada ogt 3; Table I ).
uvr triple mutant), because we have previously shown that Sensitization to DBAs differences in sensitivity to mutagenesis by both long-chain In marked contrast to the results obtained with the alkylating alkylating agents (10) and DBAs (6) between AGT-proficient agents, bacteria carrying the wild-type AGT or the V139F and -deficient bacteria are vastly increased in a Uvr defective mutant version were substantially more sensitive than control background. cells to both cytotoxicity and mutagenesis by DBE ( Figure 5 )
Escherichia coli defective strain carrying the cloning vector and DBM ( Figure 6 ). Interestingly, V139F/P140R/L142M as control (UC1292) was extremely sensitive to mutagenesis showed much lower efficiency than the other two AGTs in by low, non-cytotoxic doses of MNNG. Expression of human enhancing cytotoxicity and mutagenesis caused by DBAs.
wild-type AGT in these cells prevented most (98%) of the Inactivation of AGT by BG virtually abolished the sensitization mutagenesis induced by MNNG. Cell killing required higher promoted by the wild-type and V139F proteins; however, the MNNG concentrations, and prevention by wild-type AGT was presence of BG had no effect on the bacteria harboring V139F/ much less effective. These results are explained by differences in the contribution of O 6 -methylguanine (O 6 -meG) to the P140R/L142M. a Mutagenic potencies, expressed as Ara r mutants induced per dose of mutagen, were calculated from the corresponding dose-response curves as described in Materials and methods. Data are averages from independent experiments. SD values did not exceed 15% of the mean. All bacterial strains were assayed in parallel. mutagenesis and cytotoxicity caused by MNNG. O 6 -meG is the major cause of mutagenesis by alkylating agents in E.coli, particularly in the absence of both AGT and nucleotide excision repair (17,18). With respect to its role in cytotoxicity, unrepaired O 6 -meG lesions may trigger bacterial death through repeated, futile DNA mismatch repair (19) . Alternatively, excision repair. A dose of 4 µM MNNG increased the background level of Ara r mutants 4.5 times in bacteria expressing the wild-type protein, while those expressing V139F Subtle differences between wild-type AGT and the two mutant variants were further revealed by assaying protection against remain insensitive to the mutagenic action of this methylating compound. Christians et al. (9) reported that V139F/P140R/ mutagenesis by ENU and CCNU. V139F protected bacteria against these alkylating agents with similar efficiency to wild-L142M (like V139F) is more effective than wild-type AGT in the protection of E.coli from MNNG-induced cell killing.
type AGT, in contrast to the higher levels of protection provided by this mutant against MNNG. V139F/P140R/L142M Though we were able to repeat this finding using bacteria lacking AGT and nucleotide excision repair, we did not detect protected E.coli from ENU mutagenesis with lower efficiency (up to 5-fold) than the wild-type. Hence, conclusions based significant differences in the abilities of these two AGTs to protect bacteria from the mutagenic effects of low doses of on protection against MNNG mutagenesis do not necessarily apply to other alkylating agents such as ENU and CCNU. MNNG. It should therefore be noted that conclusions based on MNNG survival at relatively high concentrations do not BG, a competitive inhibitor and thus a potent inactivator of human wild-type AGT, is in clinical trials for sensitizing necessarily apply to the much less stringent mutagenesis assay. cytotoxic/mutagenic potential. Mutant AGTs provide us with the opportunity to examine the relative ability of wild-type and the two mutant AGTs to influence DBA cytotoxicity and mutagenesis, both in the presence or the absence of the AGT inhibitor, BG. As reported previously (7), expression in E.coli of wild-type AGT caused a remarkable increase in mutagenesis and lethality upon exposure to DBE and DBM. Here we further demonstrate that the AGT-mediated sensitization to DBAs can be reversed by depleting AGT with BG, indicating an absolute requirement for active AGT in this response. Moreover, we show that although the single substitution V139F has little effect on the protein's ability to promote DBA genotoxicity, the triple substitution V139F/P140R/L142M rendered this variant virtually unable to potentiate toxicity or mutagenesis by DBAs.
As it has already been mentioned, the resistance of V139F/ P140R/L142M to depletion by BG has been attributed to steric hindrance at the active site, provoked primarily by the substitution of the proline residue at position 140 (9, 14) . The diminished ability of V139F/P140R/L142M to sensitize E.coli to the lethal and mutagenic effects of DBE and DBM may also be due to such a steric effect. In the case of DBE, one can additionally speculate that insertion of arginine possessing a positively charged side chain at position 140 might prevent the attack by the reactive episulfonium ion. We have reported previously that the E.coli Ada AGT is unable to promote DBA mutagenicity. The other bacterial AGT, Ogt does enhance indicate that the proline residue at position 140 is important for the ability of AGTs to promote DBA genotoxicity.
Whilst the mechanism by which the human AGT promotes tumors to alkylating agents. The results reported here confirm and extend previous studies on the resistance of V139F/P140R/ DBA genotoxicity has yet to be established in detail, the recent findings that human AGT sensitizes human fibroblasts to L142M to concentrations of BG as high as 100 µM (9). It has been proposed that BG-resistant AGT mutants have a more both the lethal and mutagenic effects of DBE (N.Abril and G.P.Margison, personal communication) supports the idea that sterically hindered active site, preventing the relatively large benzyl group from entering (9, 21) . This may also explain high levels of human AGT expression might be an increased risk factor in both the toxic and mutagenic effects of environwhy V139F/P140R/L142M is less effective at preventing mutagenesis by larger size alkylating agents. mentally relevant DBAs. The results also indicate that different mutant AGTs might be used in cancer gene therapy either to In vitro and in vivo DNA adduct formation by DBE is dependent on metabolic conversion via conjugation with protect normal tissues or to ablate tumor cells. The observation that the V139F/P140R/L142M variant is incapable of promotglutathione (GSH). The half-mustard formed from DBE rearranges to form a reactive episulfonium ion, which is ing the deleterious actions of DBAs increases the interest of creating new mutant AGTs for protecting host tissue, as AGTs thought to be the ultimate metabolite that can react with DNA (3). A similar mechanism has been proposed for dihalohave been proposed to be used in gene therapy for the protection of susceptible cell populations, particularly bone methanes (22). The role of GSH in the metabolic activation of these chemical carcinogens is rather unusual, considering marrow. As a result it may be feasible to limit the major toxicity of alkylating agents. The finding that AGTs can it is generally thought of as a detoxifying agent. In contrast to the familiar role that AGT plays in protecting cells from activate DNA damaging agents presents the possibility that mutant AGTs created for the ability to activate specific alkylating agents, we have recently reported that bacterial or mammalian DNA AGTs can sensitize E.coli to both lethality prodrugs might be used directly for ablation of tumors. The introduction of genes expressing these mutant enzymes into and mutagenesis by DBAs (6, 7) . Such studies are consistent with the following two hypotheses. (i) DBA reacts first with tumors may render them specifically susceptible to particular chemotherapeutic agents as exemplified by the DBAs. the active site cysteine of AGT. Such a reaction would activate the compound, as postulated for the GSH-dependent activation
